Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.76 |
| ▸ | GAA | P10253 | 7/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.76 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.76 |
| ▸ | GFER | P55789 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.76 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | CASP6 | P55212 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061748 | 0.94 | MAPT (0.69) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL3334063 | 0.86 | GFER (0.65) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL20346925 | 0.85 | GFER (0.68) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL28512583 | 0.83 | GFER (0.61) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL17320489 | 0.83 | AKR1C3 (0.61) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL24451826 | 0.83 | AKR1C3 (0.62) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL20424995 | 0.83 | GFER (0.61) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL28758087 | 0.83 | KDM4E (0.61) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL23355312 | 0.83 | MAPT (0.56) | MAPTGAAALOX15ALOX12GFER | |
| SCHEMBL20306323 | 0.82 | GFER (0.59) | MAPTGAAALOX15ALOX12GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2975042-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | MAPT 4441/4885GAA 2722/4885ALOX15 539/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885GAA 3793/4885ALOX15 3679/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MAPT 3442/4885GAA 4105/4885ALOX15 1372/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885GAA 3793/4885ALOX15 3679/4885 |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | MAPT 3248/4885GAA 1221/4885ALOX15 4371/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885GAA 3793/4885ALOX15 3679/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | MAPT 3127/4885GAA 3793/4885ALOX15 3679/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | MAPT 634/4885GAA 499/4885ALOX15 4133/4885 |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | MAPT 1238/4885GAA 729/4885ALOX15 4472/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | MAPT 4633/4885GAA 2424/4885ALOX15 582/4885 |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | MAPT 1238/4885GAA 729/4885ALOX15 4472/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | MAPT 1238/4885GAA 729/4885ALOX15 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.